EUVIMEDEUVIMED entdecken
Crossref

The Small Molecule DDOX Confers Neuroprotection and Alleviates Motor Deficits in a Preclinical Rat Model of Parkinson’s Disease

Lorena Borges, Glauce Crivelaro do Nascimento, Laurent Ferrié, Rita Raisman-Vozari, Bruno Figadère, Patrick Pierre Michel, Elaine Del-Bel

Neurotoxicity Research · 2025

DOI: 10.1007/s12640-025-00772-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurotoxicity Research, 2025. Verfasst von Lorena Borges und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology/Neuroscience, Medical School, University of São Paulo, Ribeirão Preto, Brazil. Hauptthemen laut MEDLINE: Neuroprotective Agents, Parkinsonian Disorders. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Program Investissements d'Avenir, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tetracycline-derived compounds with anti-inflammatory properties have demonstrated neuroprotective potential in preclinical models of Parkinson's disease. In this study, we investigated the efficacy of DDOX (4-dedimethylamino 12a-deoxydoxycycline), a novel non-antibiotic tetracycline derivative. We used an intrastriatal unilateral 6-hydroxydopamine (6-OHDA) lesion paradigm in rats, which leads to partial nigrostriatal dopaminergic denervation. Our goal was to assess whether DDOX could preserve nigrostriatal dopaminergic integrity, reduce lesion-associated glial responses in the striatum, and improve motor function. Daily administration of DDOX (20 mg/kg, subcutaneously), beginning five days prior to lesion and continuing for fifteen days post-lesion, significantly attenuated the loss of dopaminergic terminals in the dorsal striatum and that of dopaminergic cell bodies in the ventral substantia nigra, as indicated by tyrosine hydroxylase (TH) immunostaining analysis. DDOX also markedly suppressed lesion-induced glial responses in the striatum. Behavioral assessments revealed that DDOX preserved motor performance, as evidenced by improved forelimb use (stepping test), maintained coordination and balance (rotarod), and maintained spontaneous locomotion (open field - actimeter). Additionally, DDOX significantly diminished amphetamine-induced rotational asymmetry, suggesting preservation of dopaminergic tone. Notably, the extent of functional recovery exceeded the degree of TH-immunoreactive nerve terminal preservation, indicating that DDOX's benefits may extend beyond dopaminergic neuroprotection. Further studies are warranted to elucidate the underlying mechanisms of these effects and confirm DDOX's efficacy in other Parkinson's disease models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroprotective AgentsParkinsonian DisordersAnimalsMaleOxidopamineRatsDisease Models, AnimalTyrosine 3-MonooxygenaseRats, Sprague-DawleyMotor ActivitySubstantia NigraCorpus StriatumDopaminergic Neurons

Stichwörter der Autor:innen

Glial inflammationMotor recoveryNeuroprotectionNon-antibiotic tetracyclineParkinson’s disease rodent model

Substanzen

Neuroprotective AgentsOxidopamineTyrosine 3-Monooxygenase

Autor:innen und Institutionen

  • Department of Neurology/Neuroscience, Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Department of Basic and Oral Biology, School of Odontology, University of São Paulo, Ribeirão Preto, Brazil.
  • Université Paris-Saclay, BioCIS, CNRS, Orsay, 91190, France.
  • Paris Brain Institute, Sorbonne University, INSERM, CNRS, Paris, France.
  • Paris Brain Institute, Sorbonne University, INSERM, CNRS, Paris, France. patrick.michel@icm-institute.org.
  • Sorbonne Université, Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, 75013, France. patrick.michel@icm-institute.org.

Förderung

  • Program Investissements d'Avenir
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Program Investissements d’Avenir
  • Association France Parkinson, Neuroscience Acceleration Launchpad NeurAL-2023

Zitieren

APA

Borges, L., do Nascimento, G. C., Ferrié, L., Raisman-Vozari, R., Figadère, B., Michel, P. P., & Del-Bel, E. (2025). The Small Molecule DDOX Confers Neuroprotection and Alleviates Motor Deficits in a Preclinical Rat Model of Parkinson’s Disease. Neurotoxicity Research. https://doi.org/10.1007/s12640-025-00772-0

Vancouver

Borges L, do Nascimento GC, Ferrié L, Raisman-Vozari R, Figadère B, Michel PP, et al. The Small Molecule DDOX Confers Neuroprotection and Alleviates Motor Deficits in a Preclinical Rat Model of Parkinson’s Disease. Neurotoxicity Research. 2025. doi:10.1007/s12640-025-00772-0

BibTeX
@article{Borges2025,
  author = {Borges, Lorena and do Nascimento, Glauce Crivelaro and Ferrié, Laurent and Raisman-Vozari, Rita and Figadère, Bruno and Michel, Patrick Pierre and Del-Bel, Elaine},
  title = {The Small Molecule DDOX Confers Neuroprotection and Alleviates Motor Deficits in a Preclinical Rat Model of Parkinson’s Disease},
  journal = {Neurotoxicity Research},
  year = {2025},
  doi = {10.1007/s12640-025-00772-0}
}
Kostenlos starten →